Dovato vs. Juluca

Dovato (dolutegravir and lamivudine) and Juluca (dolutegravir and rilpivirine) are combinations of integrase strand transfer inhibitors (INSTIs) and nucleoside analogue reverse transcriptase inhibitors (NRTIs) used as complete regimens to treat human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known substitutions associated with resistance to the individual components of either drug.

Side effects of Dovato and Juluca that are similar include headache and diarrhea.

Side effects of Dovato that are different from Juluca include nausea, insomnia, fatigue, and dizziness.

Both Dovato and Juluca may interact with other antiretroviral medications, dofetilide, metformin, anticonvulsants, St. John's wort, some antacids, cation-containing products or laxatives, sucralfate, buffered medications, and oral calcium and iron supplements (including multivitamins containing calcium or iron).

Dovato may also interact with rifampin and sorbitol.

Juluca may also interact with antimycobacterials, glucocorticoids, H2-receptor antagonists, macrolide or ketolide antibiotics, narcotic analgesics, and proton pump inhibitors (PPIs).

Common side effects of Dovato include:

• headache,
• diarrhea,
• nausea,
• insomnia,
• fatigue, and
• dizziness

Common side effects of Juluca include:

• diarrhea and
• headache.
• other antiretroviral medications,
• dofetilide,
• metformin,
• antacids,
• anticonvulsants,
• antimycobacterials,
• glucocorticoids,
• H2-receptor antagonists,
• St John's wort,
• macrolide or ketolide antibiotics,
• cation-containing products or laxatives,
• sucralfate,
• buffered medications,
• narcotic analgesics,
• oral calcium and iron supplements (including multivitamins containing calcium or iron),
• and proton pump inhibitors (PPIs).

Dovato (dolutegravir and lamivudine) is a combination of an integrase strand transfer inhibitor (INSTI) and a nucleoside analogue reverse transcriptase inhibitor (NRTI) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known substitutions associated with resistance to the individual components of Dovato.

Juluca (dolutegravir and rilpivirine) is a combination of a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) and an HIV-1non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca.

Dovato may interact with other antiretroviral drugs for the treatment of HIV-1 infection, dofetilide, metformin, anticonvulsants, rifampin, St. John's wort, cation-containing antacids or laxatives, sucralfate, buffered medications, oral calcium and iron supplements (including multivitamins containing calcium or iron), and sorbitol.

Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Juluca; it is unknown how it would affect a fetus. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Juluca during pregnancy. It is unknown if Juluca passes into breast milk, however, breastfeeding is not recommended due to the potential for HIV transmission.

The dose of Dovato is one tablet taken orally once daily with or without food.

The dose of Juluca is one tablet taken orally once daily with a meal. Juluca may interact with: